Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps
UPB•Phase 3 plans for verekitug
Upstream Bio set pivotal Phase 3 plans for verekitug in severe asthma and CRSwNP, using 400 mg subcutaneous dosing every 12 weeks.
One placebo-controlled Phase 3 trial is planned per indication, totaling about 1,500 patients across both studies.
Enrollment will include broad populations without baseline biomarker restrictions, targeting differentiated quarterly at-home administration.
The trials are targeted to start in Q1 2027, positioning for potential FDA BLA filings in both indications.
Supportive Phase 3 results could enable a launch as early as 2030.
